Hims & Hers shares tumble as FDA resolves weight problems drug scarcity

Investing.com — Shares of Hims & Hers Well being, Inc. (NYSE: HIMS) fell sharply by 15% after the U.S. Meals and Drug Administration (FDA) introduced the decision of the tirzepatide injection scarcity. The FDA’s resolution, primarily based on a complete evaluation, marks the top of a interval the place sure pharmacies may compound, distribute, or dispense the drug with out going through repercussions for violations associated to the drug’s scarcity standing.

The FDA’s re-evaluation, introduced on Thursday, December 19, 2024, reverses its earlier place from October 2, 2024, stating that the tirzepatide scarcity has ended. The company has set grace intervals till February 18, 2025, for state-licensed pharmacies, and till March 19, 2025, for outsourcing amenities to proceed compounding the drug. Nevertheless, the FDA has made it clear that it might take motion towards another statutory or regulatory violations, which may embody substandard high quality or unsafe merchandise.

The market’s response displays issues over the influence on Hims & Hers Well being, which, together with firms like WW Worldwide (NASDAQ:WW) (WeightWatchers), has been providing compounded variations of weight problems medicine like Novo Nordisk (NYSE:NVO)’s Wegovy (semaglutide). The FDA nonetheless lists semaglutide and different GLP-1 merchandise as in scarcity, with various availability reported by producers.

Buyers had been intently monitoring the FDA’s report on the scarcity standing of Eli Lilly (NYSE:LLY) & Co’s blockbuster compound, tirzepatide, with expectations set for a December 19 replace. The FDA had beforehand eliminated tirzepatide from the scarcity checklist in October however agreed to reevaluate after a lawsuit from a compounding commerce affiliation.

The FDA’s newest resolution may reshape the market dynamics for weight problems medicine, as compounded variations had been allowed underneath U.S. laws through the scarcity. Hims & Hers Well being’s inventory motion immediately is a direct response to the FDA’s announcement, signaling the top of an advantageous interval for the corporate’s compounded drug choices.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.